Skip to main content
. 2013 Jun 11;2(3):256–269. doi: 10.1016/j.molmet.2013.06.001

Figure 2.

Figure 2

Inhibition of MCP-1 release from primary monocytes by MLDL1278a is mediated by antibody binding to immobilized antigen. (A) Relative MCP-1 protein level in cell culture supernatant after primary monocytes were treated with wild-type MLDL1278a or MLDL1278a DANA mutant, both at 67 nM. The plates were precoated with increasing concentrations of MDA-LDL, as indicated. MCP-1 level from cells with MLDL1278a treatment on non-coated plates was set as 100%. (B) Binding of wild-type and DANA mutant of MLDL1278a (67 nM) to immobilized MDL-LDL at increasing concentration, under the same condition the cells are treated as in A. (C) Plates are pre-coated with MDA-LDL or native LDL (3 µg/ml) in PBS before being used for culturing monocytes with increasing concentrations of MLDL1278a. MCP-1 level from cells with MLDL1278a treatment on non-coated plates was set as 100%. (D) Binding of MLDL1278a under culturing condition (in RPMI medium with 10% serum) to immobilized MDA-LDL or LDL were examined using HRP conjugated anti-human Fc as detection antibody. Values represent the mean±SEM. Values were analyzed using two-way anova.